Education
About Us
Working with TipRanks
Follow Us
MEDI - ETF AI Analysis
Top Page
Harbor Health Care ETF (MEDI)
Rating:62Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several key holdings, such as Ascendis Pharma and AbbVie, have delivered strong year-to-date performance, supporting the ETF’s overall returns.
Focused Sector Exposure
The ETF’s heavy allocation to the health care sector provides targeted exposure to a historically resilient industry.
Solid Year-to-Date Performance
The fund has achieved strong year-to-date returns, indicating positive momentum in its portfolio.
Negative Factors
High Stock Concentration
The top two holdings, Ascendis Pharma and Eli Lilly, make up over 32% of the portfolio, increasing reliance on their performance.
Underperforming Holdings
Several holdings, including Masimo, UnitedHealth, and Vaxcyte, have shown weak year-to-date performance, which could drag on overall returns.
High Expense Ratio
The ETF’s expense ratio is relatively high, which may reduce net returns compared to lower-cost alternatives.
MEDI vs. SPDR S&P 500 ETF (SPY)
AUM23.01M
RegionGlobal
Expense Ratio0.80%
Beta0.69
IssuerHarbor
Inception DateNov 17, 2022
Dividend Yield0.43%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,292
30 Day Avg. Volume3,515
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
41.44Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering36
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MEDI Summary
The Harbor Health Care ETF (Ticker: MEDI) is a fund that focuses on the health care sector, including companies involved in biotechnology, medical devices, pharmaceuticals, and health care services. It includes well-known companies like Eli Lilly & Co and AbbVie, which are leaders in medical innovation and treatments. Investors might consider MEDI for its potential growth opportunities driven by advancements in health care technology and increasing global demand for medical solutions. However, new investors should be aware that the ETF’s performance is closely tied to the health care industry, which can be affected by regulatory changes and market conditions.
How much will it cost me?The Harbor Health Care ETF (MEDI) has an expense ratio of 0.8%, meaning you’ll pay $8 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized health care companies rather than tracking a broad index.
What would affect this ETF?The Harbor Health Care ETF (MEDI) could benefit from increasing global demand for health care services driven by aging populations, technological advancements, and innovation in biotechnology and pharmaceuticals. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could impact funding for health care initiatives or the profitability of its top holdings like Eli Lilly and AbbVie. Its global exposure also makes it sensitive to international health policies and economic conditions.
MEDI Top 10 Holdings
The Harbor Health Care ETF (MEDI) is leaning heavily on Eli Lilly, whose rising performance and strategic pipeline advancements are driving the fund’s momentum. Ascendis Pharma and AbbVie are steady contributors, though valuation concerns and mixed technical signals temper their impact. On the flip side, Legend Biotech is lagging, weighed down by profitability challenges and bearish trends. The fund’s concentration in health care, particularly biotech and pharmaceuticals, highlights its focus on innovation, but mixed results from smaller names like Masimo and Vaxcyte suggest some turbulence. With global exposure, MEDI offers a dynamic yet specialized play on health care growth.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 19.17% | $4.46M | $928.57B | 24.82% | 72 Outperform | |
| Ascendis Pharma | 16.97% | $3.94M | $12.01B | 49.86% | 46 Neutral | |
| AbbVie | 6.81% | $1.58M | $394.11B | 29.14% | 66 Neutral | |
| Legend Biotech | 5.83% | $1.36M | $4.41B | -34.82% | 46 Neutral | |
| Masimo | 4.14% | $962.60K | $7.45B | -19.85% | 54 Neutral | |
| Vaxcyte | 3.79% | $881.37K | $5.86B | -52.24% | 50 Neutral | |
| Revolution Medicines | 3.61% | $838.53K | $15.04B | 67.74% | 52 Neutral | |
| UnitedHealth | 3.48% | $808.12K | $293.13B | -38.45% | 72 Outperform | |
| ADMA Biologics | 2.85% | $661.92K | $4.71B | 1.78% | 78 Outperform | |
| Natera | 2.71% | $631.08K | $32.58B | 39.50% | 73 Outperform |
MEDI Technical Analysis
Positive
―
Price Trends
30.58
Positive
29.10
Positive
27.38
Positive
Market Momentum
0.24
Positive
46.96
Neutral
8.03
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MEDI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 31.73, equal to the 50-day MA of 30.58, and equal to the 200-day MA of 27.38, indicating a neutral trend. The MACD of 0.24 indicates Positive momentum. The RSI at 46.96 is Neutral, neither overbought nor oversold. The STOCH value of 8.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MEDI.
MEDI Peer Comparison
Comparison Results
Performance Comparison
MEDI
Harbor Health Care ETF
31.01
5.45
21.32%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
BMED
Future Health ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents